228 related articles for article (PubMed ID: 9682357)
1. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana.
González CR; Noriega FR; Huerta S; Santiago A; Vega M; Paniagua J; Ortiz-Navarrete V; Isibasi A; Levine MM
Vaccine; 1998; 16(9-10):1043-52. PubMed ID: 9682357
[TBL] [Abstract][Full Text] [Related]
2. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63.
Connell ND; Medina-Acosta E; McMaster WR; Bloom BR; Russell DG
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11473-7. PubMed ID: 8265576
[TBL] [Abstract][Full Text] [Related]
3. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
Coler RN; Skeiky YA; Bernards K; Greeson K; Carter D; Cornellison CD; Modabber F; Campos-Neto A; Reed SG
Infect Immun; 2002 Aug; 70(8):4215-25. PubMed ID: 12117930
[TBL] [Abstract][Full Text] [Related]
5. CTL responses to Leishmania mexicana gp63-cDNA vaccine in a murine model.
Ali SA; Rezvan H; McArdle SE; Khodadadi A; Asteal FA; Rees RC
Parasite Immunol; 2009 Jul; 31(7):373-83. PubMed ID: 19527453
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana.
Dumonteil E; Andrade-Narvarez F; Escobedo-Ortegon J; Ramirez-Sierra MJ; Valencia-Pacheco G; Flores-Serrano A; Canto-Lara S; Arjona-Torres A
Dev Biol (Basel); 2000; 104():135-41. PubMed ID: 11713811
[TBL] [Abstract][Full Text] [Related]
7. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.
Gonzalez C; Hone D; Noriega FR; Tacket CO; Davis JR; Losonsky G; Nataro JP; Hoffman S; Malik A; Nardin E; Sztein MB; Heppner DG; Fouts TR; Isibasi A; Levine MM
J Infect Dis; 1994 Apr; 169(4):927-31. PubMed ID: 8133113
[TBL] [Abstract][Full Text] [Related]
8. Protection of C57BL/10 mice by vaccination with association of purified proteins from Leishmania (Leishmania) amazonensis.
Mora AM; Mayrink W; Costa RT; Costa CA; Genaro O; Nascimento E
Rev Inst Med Trop Sao Paulo; 1999; 41(4):243-8. PubMed ID: 10564919
[TBL] [Abstract][Full Text] [Related]
9. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-).
Xu D; McSorley SJ; Chatfield SN; Dougan G; Liew FY
Immunology; 1995 May; 85(1):1-7. PubMed ID: 7635511
[TBL] [Abstract][Full Text] [Related]
10. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response.
Alexander J; Coombs GH; Mottram JC
J Immunol; 1998 Dec; 161(12):6794-801. PubMed ID: 9862710
[TBL] [Abstract][Full Text] [Related]
11. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
[TBL] [Abstract][Full Text] [Related]
12. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection.
Rivier D; Bovay P; Shah R; Didisheim S; Mauël J
Parasite Immunol; 1999 Sep; 21(9):461-73. PubMed ID: 10476055
[TBL] [Abstract][Full Text] [Related]
13. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
Pinto EF; de Mello Cortezia M; Rossi-Bergmann B
Vaccine; 2003 Sep; 21(25-26):3534-41. PubMed ID: 12922080
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
15. Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice.
Abdelhak S; Louzir H; Timm J; Blel L; Benlasfar Z; Lagranderie M; Gheorghiu M; Dellagi K; Gicquel B
Microbiology (Reading); 1995 Jul; 141 ( Pt 7)():1585-92. PubMed ID: 7551026
[TBL] [Abstract][Full Text] [Related]
16. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.
Cote-Sierra J; Bredan A; Toldos CM; Stijlemans B; Brys L; Cornelis P; Segovia M; de Baetselier P; Revets H
Infect Immun; 2002 Jan; 70(1):240-8. PubMed ID: 11748189
[TBL] [Abstract][Full Text] [Related]
17. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
[TBL] [Abstract][Full Text] [Related]
18. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana.
Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Dumonteil E
Vaccine; 2005 Nov; 23(46-47):5372-9. PubMed ID: 16054271
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccines induce partial protection against Leishmania mexicana.
Dumonteil E; Maria Jesus RS; Javier EO; Maria del Rosario GM
Vaccine; 2003 May; 21(17-18):2161-8. PubMed ID: 12706707
[TBL] [Abstract][Full Text] [Related]
20. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
